ArticleMedical oncology (Northwood, London, England)2025
Box-Behnken-designed nanostructured lipid carriers of xanthohumol for enhanced cellular uptake in human lung cancer cell line A549: formulation, optimization, characterization, and cytotoxicity assessment.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present research aims to develop and optimize nanostructured lipid carriers (NLCs) of Xanthohumol (Xn) for treating lung cancer (LC). Xn packed NLCs were successfully prepared by hot high-pressure homogenization in conjunction with the ultrasonication method and optimized using a pseudo-ternary phase diagram followed by the Box-Behnken design (BBD). The NLCs were solidified using rotary evaporation followed by tray drying/vacuum drying. Mannitol was used for the solidification of L-Xn-NLCs. The BBD was operated using 3 factors and 3 levels for optimization of the formulation. The dependent variables were zeta potential (R1), particle size (R2), and drug entrapment efficiency (R3), while the independent variables were Beeswax (A), Lauroglycol-90 (B), and Tween 80 (C). The optimized liquid NLCs (L-Xn-NLCs) showed particle size (PS) of 101.60 ± 1.47 nm, polydispersity index (PDI) of 0.772 ± 0.029, zeta potential (ZP) of - 25.6 mV, and an entrapment efficiency (% EE) of 97.72 ± 1.05%. As a result, NLCs have a higher drug encapsulation efficiency. After drying, followed by reconstitution, the solid NLCs (S-Xn-NLCs) showed PS of 278 nm, PDI of 0.22, ZP of - 44.3 mV, and EE% of 95.5. The results of SEM and PXRD revealed the complete adsorption of S-Xn-NLCs on the surface of mannitol. The in vitro drug release and in vitro MTT assay were performed on A549 LC cells to evaluate the anticancer efficacy of S-Xn-NLCs. In 24 h, the L-Xn-NLCs, S-Xn-NLCs, and pure drug suspension had a cumulative drug release rate of 80.09 ± 0.8%, 79.8%, and 40 ± 1.1%, respectively. It was found that both pure Xn and S-Xn-NLCs reduced the proliferation of A549 cell lines at 28.21 µM, 56.42 µM, 84.63 µM, 112.84 µM, and 141 µM. However, S-Xn-NLCs exerted higher reduction in proliferation than pure Xn. The pure Xn and the S-Xn-NLCs showed anticancer potential against A549 cell lines and the IC
Indexed as
Identifiers
41123733What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.